PRODUCT MONOGRAPH. PR. Cathflo. ® alteplase, recombinant . cell line into which the cDNA for alteplase has been genetically inserted. Read all of this leaflet carefully before you What Actilyse Cathflo is and what it is used for. 2. Contents of the pack and other information. 1. Drug monographs for CATHFLO ACTIVASE provide an overview of the drug Keeping the vial of Sterile Water for Injection upright, insert the piercing pin of the .
|Published (Last):||12 May 2017|
|PDF File Size:||13.8 Mb|
|ePub File Size:||3.41 Mb|
|Price:||Free* [*Free Regsitration Required]|
Send the page ” ” to a friend, relative, colleague or yourself.
Single-Use Vial Lytic Thrombolytic – Cathflo® Activase® (alteplase)
Keeping the vial of Sterile Water for Injection upright, insert the piercing pin of inesrt transfer device provided by the manufacturer vertically into the center of the stopper. In patients with acute ischemic stroke with uncontrolled hypertension who are otherwise eligible for alteplase therapy, increase the frequency of blood pressure monitoring if systolic blood pressure is more than mmHg or diastolic blood pressure is more than mmHg.
I usually get blood catflo after a max of 60 minutes, luckily have never had to wait the full Do not use Bacteriostatic Water for Injection. If catheter function is restored, aspirate 4 to 5 mL of blood in patients weighing 10 kg or greater or 3 mL in patients weighing less than 10 kg to remove alteplase and residual clot. If therapy with defibrotide is necessary, discontinue systemic fibrinolytic therapy not including use for routine maintenance or reopening of central venous catheters prior to initiation of defibrotide therapy.
For reestablishing patency of an occluded IV catheter.
A dose of mg of alteplase is no longer recommended due to an increased incidence of intracranial bleeding. Patients should be closely monitored for signs and symptoms of bleeding when a thrombolytic agent is administered with trazodone. Upon binding to fibrin, the one-chain form of alteplase is converted to the two-chain form. Such force could cause rupture of the catheter or expulsion of the clot into the circulation.
Bleeding The most frequent adverse reaction associated with all thrombolytics in all approved indications is bleeding. Monitor clinical and laboratory response closely during concurrent use.
In my experience, one hour dwell is what we usually need. Prothrombin times stabilized during administration of both agents will cathrlo slightly when heparin is discontinued. Length of infusion depends upon indication. Excessive pressure should be avoided when Cathflo Activase is instilled into the catheter.
This will take about 2 minutes. Vials do not contain vacuum.
All ONS Member Community
Following instillation of second dose, check catheter function 30 minutes and, if needed, minutes following second instillation. Cathflo Activase should not be administered to patients with known hypersensitivity to alteplase or any component of the formulation. Three 3 hour intravenous infusion. Major An additive risk carhflo bleeding may be seen in patients receiving thrombolytic agents with thrombin inhibitors.
For subcutaneous ports, a dose of 2 mg diluted in 3 ml 0. Within 3 hours of the onset of stroke symptoms. Patients should be closely monitored for signs and symptoms of bleeding when a thrombolytic agent is administered with vilazodone.
Weight-based dosing of 0. Moderate Due to the thrombocytopenic effects of vorinostat, an additive risk of bleeding may be seen in patients receiving concomitant thrombolytic agents. The interaction of Cathflo Activase with other drugs has not been formally studied.
Aliquots retain bioactivity for 6 months. We do not trea Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term studies in animals have not been performed to evaluate the carcinogenic potential or the effect on fertility.
If the catheter is not functional after 30 minutes, allow the solution to remain for an additional 90 minutes minutes of total dwell time and assess catheter function by attempting to aspirate blood and catheter contents. I have seen no official recommendation and no study or data, but I have had multiple discussions about this practice as an effective alternative to catheter stripping or replacement due to fibrin sheath that does not respond to 2 hour dwell. Cathflo Activase should be used with caution in the presence of known or suspected infection in the psckage.
When indicated for patients with acute myocardial infarction and ST-elevation STEMIfibrinolytic therapy may be administered within 12 hours following the onset of symptoms.
Moderate Agents that may effect hemostasis including sulfinpyrazone, can increase the likelihood of hemorrhage if administered during or immediately before therapy with thrombolytic agents. Although antifibrinolytic agents can be beneficial in the treatment of thrombolytic-induced hemorrhage, the safety of concomitant administration of these agents has not been confirmed. Alteplase has not been shown to adequately treat underlying deep vein thrombosis in patients with pulmonary embolism.
If there is still no blood return, a catheter dye study will be ordered. Major An additive risk of bleeding may be seen in patients receiving thrombolytic agents and anticoagulants. FDA-approved dosing with Cathflo 8. However, an increase in INR from 2. Caution should be exercised with insret who have any condition for which bleeding constitutes a significant hazard.